PharMerica CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-25: Form 8-K; Period of report 2014-11-25; Description 8.01 Other Events; Details 8.01.
- 2014-11-06: Form 8-K; Period of report 2014-11-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-09-22: Form 8-K; Period of report 2014-09-17; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure; Details 1.01.
- 2014-09-17: Form 8-K/A; Period of report 2014-09-09; Description 1.02 Termination of a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-25 | 8-K | 2014-11-25 | 8.01 Other Events | 8.01 As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the "Commission") on September 12, 2014 by PharMerica Corporation (the “Corporation”), as amended by the Amendment No. 1 to Current Report on Form 8-K filed with the Commission on September 17, 2014 by the Corporation, the Corporation commenced litigation against AmerisourceBergen Drug Corporation (“Amerisource”) in the Jefferson County Circuit Court of Kentucky on September 10, 2014 (the "Lawsuit"). | form8k.htm |
| 2014-11-06 | 8-K | 2014-11-06 | 2.02 Results of Operations and Financial Condition | 2.02 On November 6, 2014, PharMerica Corporation (the “Company”) issued a press release announcing results of operations for the third quarter ended September 30, 2014, a copy of which is attached as Exhibit 99.1. | form8k.htm |
| 2014-09-22 | 8-K | 2014-09-17 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure | 1.01 On September 17, 2014, PharMerica Corporation (the “Corporation”) entered into a Credit Agreement by and among the Corporation, the lenders named therein (the “Lenders”), Bank of America, N.A, as administrative agent, JPMorgan Chase Bank, N.A., as syndication agent, and U.S. Bank, National Association, Citibank, N.A., MUFG Union Bank, N.A., BBVA Compass Bank and Suntrust Bank as co-documentation agents (the “Credit Agreement”). 1.02 Effective as of September 17, 2014, in connection with the Corporation’s entry into the Credit Agreement, the Former Credit Agreement was terminated. 2.03 The information provided in Item 1.01 of this Form 8-K is hereby incorporated into this Item 2.03. 7.01 On September 19, 2014, the Corporation issued a press release announcing its entry into the Credit Agreement. | form8k.htm |
| 2014-09-17 | 8-K/A | 2014-09-09 | 1.02 Termination of a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On September 10, 2014, PharMerica Corporation (the "Company") issued a press release announcing the completion of an acquisition, changes to its 2014 earnings guidance, and comments on the AmerisourceBergen contract. 8.01 On September 9, 2014, the Company provided notice to AmerisourceBergen Drug Corporation (“Amerisource”), the Company’s wholesale supplier of pharmaceutical products, of Amerisource’s breaches of its obligations under the Amended and Restated Prime Vendor Agreement, as amended (the “Prime Vendor Agreement”), between the Company and Amerisource. | form8ka.htm |
| 2014-09-12 | 8-K | 2014-09-09 | 1.02 Termination of a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On September 10, 2014, PharMerica Corporation (the "Company") issued a press release announcing the completion of an acquisition, changes to its 2014 earnings guidance, and comments on the AmerisourceBergen contract. 8.01 On September 9, 2014, the Company provided notice to AmerisourceBergen Drug Corporation (“Amerisource”), the Company’s wholesale supplier of pharmaceutical products, of Amerisource’s breaches of its obligations under the Amended and Restated Prime Vendor Agreement, as amended (the “Prime Vendor Agreement”), between the Company and Amerisource. | form8k.htm |
| 2014-08-05 | 8-K | 2014-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2014, PharMerica Corporation (the “Company”) issued a press release announcing results of operations for the second quarter ended June 30, 2014, a copy of which is attached as Exhibit 99.1. | form8k.htm |
| 2014-06-19 | 8-K | 2014-06-17 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2014 Annual Meeting of Stockholders of the Company was held on June 17, 2014. | form8k.htm |
| 2014-06-03 | 8-K | 2014-05-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 30, 2014, PharMerica Corporation (the "Company") amended and restated its Employment Agreement (the "Employment Agreement") with David W. Froesel, Jr. ("Froesel"), the Company's Executive Vice President, Chief Financial Officer and Treasurer, to change the vesting and exercise period of Froesel’s equity compensation awards in connection with the termination of his employment and to make other limited revisions. | form8k.htm |
| 2014-05-01 | 8-K | 2014-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 On May 1, 2014, PharMerica Corporation (the “Company”) issued a press release announcing results of operations for the first quarter ended March 31, 2014, a copy of which is attached as Exhibit 99.1. | form8k.htm |
| 2014-03-17 | 8-K | 2014-03-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.02 Explanatory Note: References in this Current Report on Form 8-K to the Corporation’s 2013 Named Executive Officers do not include Michael J. Culotta, the Corporation’s former Executive Vice President and Chief Financial Officer, Anthony A. Hernandez, the Corporation’s former Senior Vice President of Human Resources, or William Monast, the Corporation’s former Executive Vice President of Sales and Client Management. 5.03 On March 11, 2014, the Corporation’s Board of Directors amended the Corporation’s Amended and Restated By-Laws to add a new Section 8.04 providing an exclusive forum provision for the adjudication of certain disputes. | form8k.htm |
| 2014-03-05 | 8-K | 2014-02-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 27, 2014, PharMerica Corporation (the “Corporation”) amended and restated its Letter Agreement with Gregory Weishar, the Chief Executive Officer of the Corporation, (the “Agreement”) to extend the term of the Agreement and to make other limited revisions. | form8k.htm |
| 2014-02-28 | 8-K | 2014-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2014, PharMerica Corporation (the “Company”) issued a press release announcing results of operations for the fourth quarter and year ended December 31, 2013, a copy of which is attached as Exhibit 99.1. | form8k.htm |
| 2014-01-13 | 8-K | 2014-01-10 | 7.01 Regulation FD Disclosure | 7.01 On January 10, 2014, PharMerica Corporation (the "Company") held a conference call with interested investors and financial analysts (the "Conference Call") to discuss the Company's 2013 and 2014 guidance. | form8-k.htm |
| 2014-01-09 | 8-K | 2014-01-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 The employment of Anthony A. Hernandez, the Senior Vice President of Human Resources of PharMerica Corporation terminated on January 3, 2014. | form8k.htm |